Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Neurocrine Biosciences, Inc. or Vertex Pharmaceuticals Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and Neurocrine Biosciences, Inc., Vertex Pharmaceuticals Incorporated Stock News

As of September 4, 2026, Neurocrine Biosciences, Inc. had a $15.8 billion market capitalization, compared to the Biotechnology median of $282.4 million. Neurocrine Biosciences, Inc.’s stock is up 9.7% in 2026, up 1% in the previous five trading days and up 10.86% in the past year.

Currently, Neurocrine Biosciences, Inc.’s price-earnings ratio is 22.8. Neurocrine Biosciences, Inc.’s trailing 12-month revenue is $3.4 billion with a 20.9% net profit margin. Year-over-year quarterly sales growth most recently was 39.5%. Analysts expect adjusted earnings to reach $10.197 per share for the current fiscal year. Neurocrine Biosciences, Inc. does not currently pay a dividend.

As of September 4, 2026, Vertex Pharmaceuticals Incorporated had a $138.4 billion market cap, putting it in the 98th percentile of all stocks. Vertex Pharmaceuticals Incorporated’s stock is up 20.5% in 2026, up 0.8% in the previous five trading days and up 37.59% in the past year.

Currently, Vertex Pharmaceuticals Incorporated’s price-earnings ratio is 31.8. Vertex Pharmaceuticals Incorporated’s trailing 12-month revenue is $12.6 billion with a 35.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.5%. Analysts expect adjusted earnings to reach $16.657 per share for the current fiscal year. Vertex Pharmaceuticals Incorporated does not currently pay a dividend.

How We Compare Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated Stock Value Grades

Company	Ticker	Value
Neurocrine Biosciences, Inc.	NBIX	D
Vertex Pharmaceuticals Incorporated	VRTX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Neurocrine Biosciences, Inc. has a Value Score of 25, which is Expensive. Vertex Pharmaceuticals Incorporated has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Neurocrine Biosciences, Inc. or Vertex Pharmaceuticals Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Neurocrine Biosciences, Inc. or Vertex Pharmaceuticals Incorporated is the better investment when it comes to value.

Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated’s Quality Grades

Company	Ticker	Quality
Neurocrine Biosciences, Inc.	NBIX	A
Vertex Pharmaceuticals Incorporated	VRTX	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Neurocrine Biosciences, Inc. has a Quality Score of 86, which is Very Strong. Vertex Pharmaceuticals Incorporated has a Quality Score of 88, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated have a grade of A. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated’s Momentum Grades

Company	Ticker	Momentum
Neurocrine Biosciences, Inc.	NBIX	C
Vertex Pharmaceuticals Incorporated	VRTX	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Neurocrine Biosciences, Inc. has a Momentum Score of 41, which is Average. Vertex Pharmaceuticals Incorporated has a Momentum Score of 76, which is Strong.

The Momentum Grade Winner: Vertex Pharmaceuticals Incorporated

As you can clearly see from the Momentum Grade breakdown above, Vertex Pharmaceuticals Incorporated is considered to have stronger momentum compared to Neurocrine Biosciences, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Vertex Pharmaceuticals Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Neurocrine Biosciences, Inc. or Vertex Pharmaceuticals Incorporated Stock?

Overall, Neurocrine Biosciences, Inc. stock has a Value Score of 25, Momentum Score of 41 and Quality Score of 86.

Vertex Pharmaceuticals Incorporated stock has a Value Score of 14, Momentum Score of 76 and Quality Score of 88.

Comparing Neurocrine Biosciences, Inc. and Vertex Pharmaceuticals Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.